title: Monitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrations.
abstract: BACKGROUND
  Acute phase proteins (APPS) include haptoglobin (Hp), C-reactive protein (CRP) and serum amyloid A (SAA). Increased Hp concentrations may be induced by endogenous or exogenous glucocorticoids in dogs.
  
  
  OBJECTIVE
  To assess whether control of hyperadrenocorticism (HAC) affects the concentrations of Hp, CRP, SAA, alkaline phosphatase (ALKP) and cholesterol, to determine whether these analytes can be used to assess control of HAC following trilostane treatment, and whether a combination of these tests offers a valid method of assessing disease control.
  
  
  METHODS
  Hp, CRP, SAA, ALKP and cholesterol were assessed in 11 dogs with spontaneous HAC before and after treatment with trilostane. Adequate control of HAC was defined as post-ACTH cortisol less than 150 nmol/l.
  
  
  RESULTS
  Significant reductions in Hp, ALKP, cholesterol and SAA (P<0.05) but not of CRP were found after control of HAC. Only Hp, cholesterol and ALKP were moderately informative (Se & Sp>0.7) of disease control when compared to adrenocorticotropin or corticotropin (ACTH) stimulation test. SAA and CRP were unhelpful (Se & Sp<0.7). The analysis of the combination of the analytes did not improve the correlation with ACTH stimulation test.
  
  
  CONCLUSIONS
  Relying on these analytes does not provide additional information over ACTH stimulation test results when assessing control of HAC treated with trilostane.
authors.affiliation: Faculty of Veterinary Medicine, University of Glasgow, Glasgow, UK.
authors.forename: A
authors.initials: A
authors.lastname: Arteaga
authors.forename: N K
authors.initials: NK
authors.lastname: Dhand
authors.forename: T
authors.initials: T
authors.lastname: McCann
authors.forename: C M
authors.initials: CM
authors.lastname: Knottenbelt
authors.forename: A J
authors.initials: AJ
authors.lastname: Tebb
authors.forename: H
authors.initials: H
authors.lastname: Evans
authors.forename: P David
authors.initials: PD
authors.lastname: Eckersall
authors.forename: I K
authors.initials: IK
authors.lastname: Ramsey
mesh_terms: D000209:Acute-Phase Proteins / Q000032:analysis / Q000378:metabolism*; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D013196:Dihydrotestosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004283:Dog Diseases / Q000097:blood* / Q000188:drug therapy*; D004285:Dogs; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006242:Haptoglobins / Q000378:metabolism; D006929:Hyperaldosteronism / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D000685:Serum Amyloid A Protein / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; D004791:Enzyme Inhibitors; D006242:Haptoglobins; D000685:Serum Amyloid A Protein; D013196:Dihydrotestosterone; D002097:C-Reactive Protein; D000469:Alkaline Phosphatase; C009954:trilostane